Atara Biotherapeutics, Inc.
ATRA· Nasdaq
Released Aug 11, 2025, after the close
10-Q filed Aug 11, 2025, 42 days after period end · 0000950170-25-106550
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Revenue | $17.58M | $28.64M | $957.00K | $51.58M |
| Net Income | $2.39M | -$19.05M | -$71.11M | $18.47M |
| EPS Diluted |
Atara Biotherapeutics, Inc. · CIK 1604464 · Engraved from SEC EDGAR
| $0.19 |
| -$3.10 |
| -$16.91 |
| $0.18 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.